In Vivo Instability of (177)Lu-DOTATATE During Peptide Receptor Radionuclide Therapy

Peptide receptor radiotherapy using (177)Lu-labeled somatostatin ligand analogs is a well-established treatment for neuroendocrine tumors, with (177)Lu-DOTATATE having acquired marketing authorization in Europe and the United States. The investigation of the pharmacokinetics of these radiopharmaceut...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Nucl Med
Päätekijät: Lubberink, Mark, Wilking, Helena, Öst, Amalia, Ilan, Ezgi, Sandström, Mattias, Andersson, Camilla, Fröss-Baron, Katarzyna, Velikyan, Irina, Sundin, Anders
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Society of Nuclear Medicine 2020
Aiheet:
Theranostics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7456166/
https://ncbi.nlm.nih.gov/pubmed/32005767
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.119.237818
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia